You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anthracycline-refractory TNBC

Showing 1 - 25 of 9,508
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple Negative Breast Cancer, Anthracycline-refractory TNBC Trial in Houston (Docetaxel, Pembrolizumab, IL-12 gene therapy)

Suspended
  • Triple Negative Breast Cancer
  • Anthracycline-refractory TNBC
  • Houston, Texas
    Houston Methodist Cancer Center
Mar 28, 2022

TNBC - Triple-Negative Breast Cancer Trial (epirubicin,cyclophosphamide,paclitaxel,Carrelizumab,

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • (no location specified)
May 8, 2023

Triple-negative Breast Cancer Trial in Shanghai (Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or

Recruiting
  • Triple-negative Breast Cancer
  • Pyrotinib with Capecitabine
  • +6 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 8, 2022

Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)

Not yet recruiting
  • Triple-negative Breast Cancer
  • A1: SHR-A1811
  • +11 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 19, 2023

Triple Negative Breast Cancer Trial (biological, drug, radiation)

Withdrawn
  • Triple Negative Breast Cancer
  • avelumab
  • +17 more
  • (no location specified)
Mar 17, 2021

Breast Cancer, Triple Negative Breast Cancer Trial in Los Angeles (Durvalumab, Radiation Therapy, Carboplatin)

Withdrawn
  • Breast Cancer
  • Triple Negative Breast Cancer
  • Los Angeles, California
    Cedars Sinai Medical Center
Aug 19, 2021

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)

Recruiting
  • Triple Negative Breast Cancer
  • +14 more
  • LYL797
  • Scottsdale, Arizona
  • +10 more
Jan 30, 2023

Breast Cancer, Triple Negative Breast Tumors Trial in Sweden (epirubicin, cyclophosphamide, paclitaxel, carboplatin, epirubicin,

Recruiting
  • Breast Cancer
  • Triple Negative Breast Neoplasms
  • epirubicin, cyclophosphamide, paclitaxel, carboplatin
  • epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin
  • Borås, Sweden
  • +15 more
Jan 3, 2022

Triple-negative Breast Cancer Trial in Milano (Fasting-mimicking diet, Metformin, Preoperative chemo)

Active, not recruiting
  • Triple-negative Breast Cancer
  • Fasting-mimicking diet
  • +2 more
  • Milano, Italy
    Fondazione IRCCS Istituto Nazionale Tumori
Jan 17, 2023

Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone Trial in Houston (biological, drug, other)

Recruiting
  • Bone Sarcoma
  • +15 more
  • Aldesleukin
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 3, 2022

Triple Negative Breast Tumors Trial (Pembrolizumab, Nab-paclitaxel, Anthracycline (doxorubicin))

Completed
Has Results
  • Triple Negative Breast Neoplasms
  • Pembrolizumab
  • +5 more
  • (no location specified)
Aug 21, 2020

Triple Negative Breast Cancer Trial (Sacituzumab govitecan, Pembrolizumab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • (no location specified)
Oct 5, 2023

Solid Tumor Trial in Taichung (HLA-G-CAR.BiTE allogeneic ?d T cells)

Not yet recruiting
  • Solid Tumor
  • HLA-G-CAR.BiTE allogeneic γδ T cells
  • Taichung, Non-US, Taiwan
    China Medical University Hospital
Nov 27, 2023

Advanced Solid Tumor, Triple Negative Breast Cancer Trial (Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II))

Not yet recruiting
  • Advanced Solid Tumor
  • Triple Negative Breast Cancer
  • Pembrolizumab & ADG106 (Phase Ib)
  • Pembrolizumab & ADG106 (Phase II)
  • (no location specified)
Aug 5, 2022

Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer Trial in United States (TH1902)

Recruiting
  • Solid Tumor
  • +8 more
  • Los Angeles, California
  • +5 more
Jun 27, 2022

Triple Negative Breast Cancer Trial in Los Angeles (biological, procedure, drug)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Aldesleukin
  • +12 more
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Aug 9, 2023

Checkpoint Inhibitors in Triple Negative Breast

Recruiting
  • Triple Negative Breast Cancer
  • Whole Genome Sequencing
  • +7 more
  • Barcelona, Spain
    Vall d'Hebron Institute of Oncology
Jun 20, 2023

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial

Not yet recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +4 more
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Jun 26, 2023

Breast Cancer Trial in Xining (Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin)

Recruiting
  • Breast Cancer
  • Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin
  • Xining, Qinghai, China
    Affiliated Hospital of Qinghai University
Apr 21, 2022

Triple Negative Breast Cancer Trial in Zhengzhou (Docetaxel +doxorubicin+ cyclophosphamide, Docetaxel +Cisplatin)

Recruiting
  • Triple Negative Breast Cancer
  • Docetaxel +doxorubicin+ cyclophosphamide
  • Docetaxel +Cisplatin
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 18, 2022

Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 Trial in United States (drug, other,

Recruiting
  • Invasive Breast Carcinoma
  • +11 more
  • Conroe, Texas
  • +4 more
May 3, 2022

Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in United States (ELU001)

Recruiting
  • Ovarian Cancer
  • +68 more
  • Phoenix, Arizona
  • +8 more
Aug 18, 2022

Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal

Recruiting
  • Breast Cancer
  • +15 more
  • ATRC-101
  • +2 more
  • Phoenix, Arizona
  • +10 more
Sep 28, 2022

Triple Negative Breast Cancer, Breast Cancer Trial in United States (Trilaciclib, Cylophosphamide, Doxorubicin)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Breast Cancer
  • Los Alamitos, California
  • +6 more
Jan 25, 2023

Breast Cancer, Triple Negative Breast Cancer, Camrelizumab Trial in Zhengzhou ((Carrelizumab + TCb) regimen, TCb regimen)

Recruiting
  • Breast Cancer
  • +2 more
  • （Carrelizumab + TCb） regimen
  • TCb regimen
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jul 24, 2022